SPECIAL NOTICE
A -- R&D DTRA Consortium Project Awards
- Notice Date
- 2/18/2014
- Notice Type
- Special Notice
- NAICS
- 611310
— Colleges, Universities, and Professional Schools
- Contracting Office
- US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014
- ZIP Code
- 21702-5014
- Solicitation Number
- DTRA13037
- Archive Date
- 2/18/2015
- Point of Contact
- Brandon Roebuck, 301-619-9207
- E-Mail Address
-
US Army Medical Research Acquisition Activity
(brandon.m.roebuck.civ@mail.mil)
- Small Business Set-Aside
- N/A
- Description
- The government intends to issue three Research and Development (R&D) contracts in support of a Defense Threat Reduction Agency (DTRA) consortium project. The project is Development of Medical Countermeasures for Botulinum Neurotoxin Intoxication Focused on Therapeutics and Neuroregenerative Medicines. DTRA has established a multicenter program in which directed research projects are submitted, evaluated and selected to sponsor a network of collaboration amongst researchers. Under the multicenter collaboration, the following three proposals were selected for funding, to be administered in coordination with US Army Medical Research Institute of Chemical Defense (USAMRICD) collaborators. a.Montclair State University (MSU): MSU will contribute to the botulinum drug discovery effort by synthesizing small molecule drug candidates for treatment of botulinum toxin exposure and optimizing their pharmaceutical properties. First year of research cost is estimated at $ 428,737. Total five year proposal cost is $2,515,123 b.UMass Dartmouth (UMD): PIs, Dr. Bal Ram Singh and Dr. Shuowei Cai. UMD will support the efforts at the USAMRICD by performing high throughput screening (HTS) of natural product and small molecule libraries. UMass Dartmouth (UMD) first year of research cost is estimated at $275,044. Total five year proposal cost is $2,876,104 c.Ossianix University: Ossianix will provide an alternative to traditional inhibitors by developing small single chain shark antibodies (VNRS) as potential inhibitors of LC catalytic activity. Ossianix first year of research cost is estimated at $214,608. Total five year proposal cost is $1 Million. This consortium type research is under the Memorandum of Agreement (MOA) between DTRA and USAMRICD. Fiscal Year 2013 DTRA funding will be obligated for these research contracts. The statutory authority permitting other than full and open competition is 10 U.S.C.2304(c)(1) as implemented by FAR 6.302-1 - Only one responsible source and no other supplies or services will satisfy agency requirements. The MOA is authorized under the Economy Act 31 USC 1535. All responses to this Notice of Intent are due by no later than 3:00 PM EST on March 5, 2014. The POC for this action is: Scot Plank Contracting Officer USAMRICD Phone Number: 410-417-2821 E-Mail Address: scot.b.plank.civ@mail.mil
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/USA/USAMRAA/DAMD17/DTRA13037/listing.html)
- Record
- SN03290361-W 20140220/140218234418-7a2cc12ad6c9141863f05a673fcba6a8 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |